Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1-3/2010

01-07-2010

Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange

Authors: Daniel S. Warren, Robert A. Montgomery

Published in: Immunologic Research | Issue 1-3/2010

Login to get access

Abstract

Human leukocyte antigen (HLA) sensitization and ABO incompatibility continue to pose significant barriers to further expansion of live donor renal transplantation. However, the recent development of effective desensitization protocols and creative paired donation strategies demonstrates that the presence of circulating donor HLA-specific antibodies and the use of ABO incompatible organs should no longer be considered contraindications for renal transplantation. It is estimated that as many as 6,000 patients on the kidney transplant waiting list have incompatible living donors and could benefit from these treatments. Furthermore, as our understanding of these treatment modalities has improved, it is now possible to predict whether desensitization, kidney paired donation or a combination of both will provide an individual patient with their best chance for successful renal transplantation.
Literature
1.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.CrossRefPubMed
2.
Ratner LE, Ciseck LJ, Moore RG, Cigarroa FG, Kaufman HS, Kavoussi LR. Laparoscopic live donor nephrectomy. Transplantation. 1995;60:1047–9.PubMed
3.
Ratner LE, Kavoussi LR, Sroka M, Hiller J, Weber R, Schulam PG, et al. Laparoscopic assisted live donor nephrectomy–a comparison with the open approach. Transplantation. 1997;63:229–33.CrossRefPubMed
4.
Ratner LE, Montgomery RA, Maley WR, Cohen C, Burdick J, Chavin KD, et al. Laparoscopic live donor nephrectomy: the recipient. Transplantation. 2000;69:2319–23.CrossRefPubMed
5.
Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;2:662–5.CrossRefPubMed
6.
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–9.PubMed
7.
8.
Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F. “Hyperacute” renal-homograft rejection in man. N Engl J Med. 1968;279:611–8.PubMedCrossRef
9.
Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA. Kidney paired donation and optimizing the use of live donor organs. JAMA. 2005;293:1883–90.CrossRefPubMed
10.
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–55.CrossRefPubMed
11.
Glotz D, Antoine C, Julia P, Pegaz-Fiornet B, Duboust A, Boudjeltia S, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int. 2004;17:1–8.CrossRefPubMed
12.
Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2:758–60.CrossRefPubMed
13.
Jordan S, Tyan D, Stablein D, Mcintosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256–62.CrossRefPubMed
14.
Jordan SC, Vo A, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6:459–66.CrossRefPubMed
15.
Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887–95.CrossRefPubMed
16.
Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003;75:971–7.CrossRefPubMed
17.
Gloor JM, Lager D, Fidler M, Grande JP, Moore SB, Winters J, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation. 2005;80:1572–7.CrossRefPubMed
18.
Montgomery R, Locke J, King K, Segev D, Warren DS, Kraus E, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation. 2009;87:1246–55.CrossRefPubMed
19.
Segev DL, Simpkins C, Warren D, King K, Shirey R, Maley W, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant. 2005;5:2570–5.CrossRefPubMed
20.
Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant. 2004;4:1315–22.CrossRefPubMed
21.
Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Reding R, Gianello P, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987;19:4538–42.PubMed
22.
Hume DM, Merill JP, Miller BF, Thorn DW. Experiences with renal allotransplantation in the human: report of nine cases. J Clin Invest. 1955;34:327–32.CrossRefPubMed
23.
Starzl TE, Machioro TL, Holmes JH, Hermann G, Brittain RS, Stonington OH, et al. Renal homograft’s in patients with major donor-recipient blood group incompatibilities. Surgery. 1964;55:195–200.PubMed
24.
Tanabe K, Takahashi K, Tokumoto T, Ishikawa N, Oshima T, Kanematsu A, et al. Infectious complications in ABO-incompatible living donor kidney transplantation: a single center experience. Transplant Proc. 1998;30:3130–2.CrossRefPubMed
25.
Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Moriau M, Ikabu N, et al. Splenectomy as a prerequisite for successful human ABO-incompatible renal-transplantation. Transplant Proc. 1985;17:138–43.
26.
Locke J, Magro CM, Singer A, Segev D, Haas M, Hillel A, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9:231–5.CrossRefPubMed
27.
Locke J, Zachary A, Haas M, Melancon J, Warren D, Simpkins C, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant. 2007;7:842–6.CrossRefPubMed
28.
Everly M, Everly J, Susskind B, Brailey P, Arend L, Alloway R, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754–61.CrossRefPubMed
29.
Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO-incompatible kidney transplantation and rituximab. Transplant Proc. 2005;37:3286–7.CrossRefPubMed
30.
Terasaki P, Gjertson D, Cecka J. Paired kidney exchange is not a solution to ABO incompatibility. Transplantation. 1998;65:291.CrossRefPubMed
31.
Montgomery RA, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA. 2005;294:1655–63.CrossRefPubMed
32.
Segev D, Kucirka LM, Gentry SE, Montgomery R. Utilization and outcomes of kidney paired donation in the United States. Transplantation. 2008;86:502–10.CrossRefPubMed
33.
Montgomery R, Gentry SE, Marks W, Warren D, Hiller J, Houp J, et al. Domino paired kidney donation: a strategy to make best use of live non-directed donation. Lancet. 2006;368:419–21.CrossRefPubMed
34.
Rees M, Kopke J, Pelletier R, Segev D, Rutter M, Fabrega AJ, et al. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med. 2009;360:1096–101.CrossRefPubMed
35.
Gentry SE, Montgomery R, Swihart B, Segev D. The roles of dominos and nonsimultaneous chains in kidney paired donation. Am J Transplant. 2009;9:1330–6.CrossRefPubMed
36.
Segev DL, Gentry SE, Melancon JK, Montgomery RA. Characterization of waiting times in a simulation of kidney paired donation. Am J Transplant. 2005;5:2448–55.CrossRefPubMed
37.
Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant. 2005;5:1914–21.CrossRefPubMed
38.
Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, et al. Successful renal transplantation across simultaneous ABO incompatible and positive cross match barriers. Am J Transplant. 2004;4:561–8.CrossRefPubMed
Metadata
Title
Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange
Authors
Daniel S. Warren
Robert A. Montgomery
Publication date
01-07-2010
Publisher
Humana Press Inc
Published in
Immunologic Research / Issue 1-3/2010
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-009-8157-y

Other articles of this Issue 1-3/2010

Immunologic Research 1-3/2010 Go to the issue

OriginalPaper

Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection

OriginalPaper

Immunogenetics and immunology in transplantation

OriginalPaper

Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence

OriginalPaper

Controlling somatic hypermutation in immunoglobulin variable and switch regions

OriginalPaper

Genetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy

OriginalPaper

Autoimmune thyroiditis research at Johns Hopkins University